We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| AstraZeneca PLC | NYSE:AZN | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 54.17 | 0 | 01:00:00 |
From Apr 2019 to Apr 2024
By Oliver Griffin
AstraZeneca PLC (AZN.LN) said Monday that the U.S. Food and Drug Administration has accepted regulatory submission for its Lynparza maintenance therapy, which is being developed to treat advanced ovarian cancer.
The pharmaceutical company said the submission of the drug, which it is developing with Merck & Co. Inc. (MRK) as part of a global strategic oncology collaboration, is based on positive results from the pivotal Phase III SOLO-1 trial.
The company said Lynparza was the first regulatory submission in the U.S. for a poly ADP ribose polymerase, or PARP, inhibitor as a first-line maintenance treatment for advanced ovarian cancer. Approval of the drug would expand the use of Lynparza to patients in the first-line setting following platinum-based chemotherapy, AstraZeneca said.
AstraZeneca said Lynparza is currently approved in more than 60 countries for the treatment of platinum-sensitive relapsed ovarian cancer.
Write to Oliver Griffin at oliver.griffin@dowjones.com; @OliGGriffin
(END) Dow Jones Newswires
November 12, 2018 02:36 ET (07:36 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year AstraZeneca Chart |
1 Month AstraZeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
